Exhibiting at HOTELEX Shanghai 2025

Bluesail Medical Co., Ltd., headquartered in Zibo, Shandong, China, is one of the most influential and diversified medical technology companies in Asia. Specializing in protective healthcare products and advanced cardiovascular and surgical devices, Bluesail is recognized globally for its high-quality manufacturing, innovative R&D, and strategic acquisitions in the medtech space.

Company Overview

Founded in 2002, Bluesail Medical has grown from a manufacturer of disposable gloves into a comprehensive medical conglomerate with operations across personal protective equipment (PPE), cardiovascular interventions, and minimally invasive surgical tools. The company is publicly listed on the Shenzhen Stock Exchange (Stock Code: 002382.SZ), and as of 2023, it operates under a multi-brand portfolio including Biosensors International, JW Medical Systems (JWMS), and Wuhan BCARE.

Core Business and Product Portfolio

Bluesail’s business is categorized into four main divisions:

• Healthcare Protective Products

  • Disposable Nitrile Gloves
  • Latex and PVC Examination Gloves
  • TPE/CPE Gloves
  • Surgical Gloves

• Cardio and Neuro Vascular Devices

  • Drug-Eluting Stents (DES)
  • PTA/PV Balloons and Stent Systems
  • Neurovascular Access Devices
  • Structural Heart Disease Solutions

• Minimally Invasive Surgical Equipment

  • Endoscopic and Anorectal Staplers
  • Ultrasonic Scalpels
  • Hemorrhoid Treatment Devices

• Emergency and First-Aid Care

  • Trauma Kits
  • Medical Dressings
  • Rescue Equipment

Each segment caters to hospital systems, surgical centers, and healthcare providers with high-performance, safety-certified medical technologies.

Unique Selling Proposition

Bluesail Medical sets itself apart through:

• Vertical integration from raw materials to finished goods
• Massive scale of PPE production, with over 30 billion gloves per year
• Strong R&D backbone, investing over 8% of annual revenue in innovation
• Global footprint, including manufacturing and R&D facilities in China, Singapore, Switzerland, and the USA
• High-level compliance with FDA, CE, ISO 13485, and MDSAP certifications

Financial Performance

According to the company’s 2023 annual report:

• Total revenue reached approximately RMB 9.87 billion (~USD 1.37 billion)
• Net profit: RMB 987 million (~USD 137 million)
• R&D investment: Over RMB 800 million
• Export operations account for 60% of total revenue, with major markets in North America, Europe, Southeast Asia, and Latin America

Global Expansion and Acquisitions

Bluesail has strategically acquired key players to strengthen its international footprint:

• Biosensors International (Singapore): A global leader in interventional cardiology
• JWMS (China): Focused on drug-eluting stents with large market share in China
• Wuhan BCARE: Specialized in critical care and emergency response products

These acquisitions have helped the company build an integrated global medtech ecosystem.

Manufacturing Capabilities

• Over 1 million square meters of GMP-compliant production facilities
• 100+ automated glove production lines in Shandong
• Cleanroom-grade facilities for cardiovascular devices in Suzhou and Singapore
• Advanced manufacturing supported by AI-driven quality control and data systems

Target Markets

Bluesail Medical primarily serves:

• Hospitals and Clinics
• Distributors and Wholesalers
• Public Health and Government Agencies
• Private Label and OEM Clients
• International Aid Organizations

The company also actively participates in global tenders for PPE and surgical devices.

Certifications and Regulatory Compliance

• ISO 13485:2016 and ISO 9001:2015 for quality management
• CE Certification for EU markets
• US FDA 510(k) cleared products
• MDSAP accreditation covering Canada, Japan, Brazil, and Australia
• Listed on WHO’s emergency procurement suppliers list

Shipments and Export Activity

Bluesail has a significant presence in global export markets:

• Exported to 120+ countries
• Over 300 international shipment entries on platforms like ImportYeti and Volza
• Partners with Fortune 500 healthcare distributors for logistics and reach
• Registered vendors for UNICEF, WHO, and other global NGOs

Awards and Recognition

• Ranked in Top 10 Global Glove Manufacturers by market share
• Named China’s Best Medical Device Brand in 2023
• Won Best Innovation in Interventional Therapy by Chinese Medical Device Association (CMDA)

Client Testimonials

“Bluesail’s nitrile gloves have been consistently high quality with excellent delivery timelines—critical during the pandemic years.”
— Procurement Officer, European Government Health Agency

“We’ve partnered with Biosensors International for over five years; their stents offer both reliability and innovation.”
— Interventional Cardiologist, Singapore General Hospital

Conclusion

Bluesail Medical Co., Ltd. exemplifies the evolution of Chinese medtech companies into globally competitive and innovation-driven enterprises. With a diverse portfolio, robust financials, international certifications, and a strong R&D pipeline, Bluesail continues to play a vital role in safeguarding health and advancing medical care around the world.